JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
Background JME-001 is a phase II trial assessing the efficacy and safety of cisplatin, pemetrexed, and nivolumab as first-line therapy in malignant pleural mesothelioma (MPM).Patients and methods Patients with untreated, unresectable MPM with an Eastern Cooperative Oncology Group (ECOG) performance...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/9/10/e003288.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849734203535523840 |
|---|---|
| author | Nobukazu Fujimoto Yosuke Miyamoto Sae Wada Katsuyuki Hotta Toshiyuki Kozuki Keisuke Aoe Jun Sakurai Michihiro Yoshida Daijiro Harada |
| author_facet | Nobukazu Fujimoto Yosuke Miyamoto Sae Wada Katsuyuki Hotta Toshiyuki Kozuki Keisuke Aoe Jun Sakurai Michihiro Yoshida Daijiro Harada |
| author_sort | Nobukazu Fujimoto |
| collection | DOAJ |
| description | Background JME-001 is a phase II trial assessing the efficacy and safety of cisplatin, pemetrexed, and nivolumab as first-line therapy in malignant pleural mesothelioma (MPM).Patients and methods Patients with untreated, unresectable MPM with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–1 were included. The primary endpoint is the centrally reviewed objective response rate. The secondary endpoints include (1) response rate assessed by investigators, (2) disease control rate, (3) overall survival, (4) progression-free survival, (5) duration of response, and (6) time to response. Safety and adverse events will also be evaluated. Cisplatin (75 mg/m2), pemetrexed (500 mg/m2), and nivolumab (360 mg/body) were administered intravenously every 3 weeks with a total of 4–6 cycles. If patients did not progress during the combination phase, maintenance therapy with nivolumab was administered until disease progression or unacceptable toxicity. Tissue samples were required and collected for programmed death ligand 1 analysis.Results Eighteen patients (mean age 69.2 years, 15 men) were enrolled between January 2018 and May 2019. The ECOG PS was 0 in 3 patients and 1 in 15 patients. Fourteen (77.8%; 95% CI 52.4% to 93.6%) patients had an objective response. The disease control rate was 94.4% (95% CI 72.7% to 99.9%). Fourteen (77.8%) patients had partial response (PR), three had stable disease, and one was not evaluable. Tumor shrinkage was observed in 10/14 (71.4%) patients with epithelioid, and 2/2 (100%) patients with sarcomatoid or biphasic histological subtype had PR. Ten (55.6%) patients experienced grade 3 or worse adverse events, including disorder of metabolism or nutrition (33.3%), loss of appetite (27.8%), anemia (16.7%), and hyponatremia (11.1%). No treatment-related deaths occurred.Conclusions The safety and efficacy of this study strongly support a definitive trial of this combination.Trial registration numberUMIN000030892. |
| format | Article |
| id | doaj-art-af8197ea96ff4fda8b8b228a37b81135 |
| institution | DOAJ |
| issn | 2051-1426 |
| language | English |
| publishDate | 2021-10-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-af8197ea96ff4fda8b8b228a37b811352025-08-20T03:07:50ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262021-10-0191010.1136/jitc-2021-003288JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesotheliomaNobukazu Fujimoto0Yosuke Miyamoto1Sae Wada2Katsuyuki Hotta3Toshiyuki Kozuki4Keisuke Aoe5Jun Sakurai6Michihiro Yoshida7Daijiro Harada8Department of Medical Oncology, Okayama Rosai Hospital, Okayama, JapanDepartment of Medical Oncology, Okayama Rosai Hospital, Okayama, JapanDepartment of Medical Oncology, Okayama Rosai Hospital, Okayama, JapanCenter of Innovative Clinical Medicine, Okayama University Hospital, Okayama, JapanDepartment of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center, Matsuyama, JapanDepartment of Medical Oncology, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, JapanCenter of Innovative Clinical Medicine, Okayama University Hospital, Okayama, JapanCenter of Innovative Clinical Medicine, Okayama University Hospital, Okayama, JapanDepartment of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center, Matsuyama, JapanBackground JME-001 is a phase II trial assessing the efficacy and safety of cisplatin, pemetrexed, and nivolumab as first-line therapy in malignant pleural mesothelioma (MPM).Patients and methods Patients with untreated, unresectable MPM with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–1 were included. The primary endpoint is the centrally reviewed objective response rate. The secondary endpoints include (1) response rate assessed by investigators, (2) disease control rate, (3) overall survival, (4) progression-free survival, (5) duration of response, and (6) time to response. Safety and adverse events will also be evaluated. Cisplatin (75 mg/m2), pemetrexed (500 mg/m2), and nivolumab (360 mg/body) were administered intravenously every 3 weeks with a total of 4–6 cycles. If patients did not progress during the combination phase, maintenance therapy with nivolumab was administered until disease progression or unacceptable toxicity. Tissue samples were required and collected for programmed death ligand 1 analysis.Results Eighteen patients (mean age 69.2 years, 15 men) were enrolled between January 2018 and May 2019. The ECOG PS was 0 in 3 patients and 1 in 15 patients. Fourteen (77.8%; 95% CI 52.4% to 93.6%) patients had an objective response. The disease control rate was 94.4% (95% CI 72.7% to 99.9%). Fourteen (77.8%) patients had partial response (PR), three had stable disease, and one was not evaluable. Tumor shrinkage was observed in 10/14 (71.4%) patients with epithelioid, and 2/2 (100%) patients with sarcomatoid or biphasic histological subtype had PR. Ten (55.6%) patients experienced grade 3 or worse adverse events, including disorder of metabolism or nutrition (33.3%), loss of appetite (27.8%), anemia (16.7%), and hyponatremia (11.1%). No treatment-related deaths occurred.Conclusions The safety and efficacy of this study strongly support a definitive trial of this combination.Trial registration numberUMIN000030892.https://jitc.bmj.com/content/9/10/e003288.full |
| spellingShingle | Nobukazu Fujimoto Yosuke Miyamoto Sae Wada Katsuyuki Hotta Toshiyuki Kozuki Keisuke Aoe Jun Sakurai Michihiro Yoshida Daijiro Harada JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma Journal for ImmunoTherapy of Cancer |
| title | JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma |
| title_full | JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma |
| title_fullStr | JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma |
| title_full_unstemmed | JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma |
| title_short | JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma |
| title_sort | jme 001 phase ii trial of first line combination chemotherapy with cisplatin pemetrexed and nivolumab for unresectable malignant pleural mesothelioma |
| url | https://jitc.bmj.com/content/9/10/e003288.full |
| work_keys_str_mv | AT nobukazufujimoto jme001phaseiitrialoffirstlinecombinationchemotherapywithcisplatinpemetrexedandnivolumabforunresectablemalignantpleuralmesothelioma AT yosukemiyamoto jme001phaseiitrialoffirstlinecombinationchemotherapywithcisplatinpemetrexedandnivolumabforunresectablemalignantpleuralmesothelioma AT saewada jme001phaseiitrialoffirstlinecombinationchemotherapywithcisplatinpemetrexedandnivolumabforunresectablemalignantpleuralmesothelioma AT katsuyukihotta jme001phaseiitrialoffirstlinecombinationchemotherapywithcisplatinpemetrexedandnivolumabforunresectablemalignantpleuralmesothelioma AT toshiyukikozuki jme001phaseiitrialoffirstlinecombinationchemotherapywithcisplatinpemetrexedandnivolumabforunresectablemalignantpleuralmesothelioma AT keisukeaoe jme001phaseiitrialoffirstlinecombinationchemotherapywithcisplatinpemetrexedandnivolumabforunresectablemalignantpleuralmesothelioma AT junsakurai jme001phaseiitrialoffirstlinecombinationchemotherapywithcisplatinpemetrexedandnivolumabforunresectablemalignantpleuralmesothelioma AT michihiroyoshida jme001phaseiitrialoffirstlinecombinationchemotherapywithcisplatinpemetrexedandnivolumabforunresectablemalignantpleuralmesothelioma AT daijiroharada jme001phaseiitrialoffirstlinecombinationchemotherapywithcisplatinpemetrexedandnivolumabforunresectablemalignantpleuralmesothelioma |